Bandu Raju, Lee Hyun Jeong, Lee Hyeong Min, Ha Tae Hyon, Lee Heon-Jeong, Kim Se Joo, Ha Kyooseob, Kim Kwang Pyo
Department of Applied Chemistry, Institute of Natural Science, Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University, Yongin 17104, Republic of Korea.
Department of Biomedical Science and Technology, Kyung Hee Medical Science Research Institute, Kyung Hee University, Seoul 02447, Republic of Korea.
Mass Spectrom (Tokyo). 2023;12(1):A0123. doi: 10.5702/massspectrometry.A0123. Epub 2023 Jul 6.
Liquid chromatography/electrospray ionization-mass spectrometry revealed plasma metabolic profiles for the antidepressant drug escitalopram (ECTP) and associated clinical responses in subjects with major depressive disorder (MDD). Metabolic profiles contribute to variations in responses to drug treatment of depression. To assess clinical responses and treatment outcomes, we quantified the levels of metabolites, including those of the parent drug, in plasma samples collected at different time points (days 0, 7, 14, and 42) during treatment of seven patients with MDD. Results showed that mean plasma levels of key metabolites and ECTP at day 7 were significantly associated with the clinical response at 42 days after treatment. Statistical analyses, including principal component analysis, of key metabolites and ECTP samples at different time points clearly distinguished the clinical responders from non-responder subjects. Although further validation with a larger cohort is necessary, our results indicate that early improvement and plasma levels of key metabolites and ECTP are predictive of therapeutic treatment outcomes and thus can be used to guide the use of ECTP.
液相色谱/电喷雾电离质谱法揭示了抗抑郁药物艾司西酞普兰（ECTP）的血浆代谢谱以及重度抑郁症（MDD）患者的相关临床反应。代谢谱导致了抑郁症药物治疗反应的差异。为了评估临床反应和治疗结果，我们对7例MDD患者治疗期间不同时间点（第0、7、14和42天）采集的血浆样本中的代谢物水平进行了量化，包括母药的代谢物水平。结果显示，第7天关键代谢物和ECTP的平均血浆水平与治疗后42天的临床反应显著相关。对不同时间点的关键代谢物和ECTP样本进行的统计分析，包括主成分分析，清楚地将临床反应者与无反应者区分开来。尽管需要用更大的队列进行进一步验证，但我们的结果表明，关键代谢物和ECTP的早期改善和血浆水平可预测治疗结果，因此可用于指导ECTP的使用。
